Zymeworks Statistics
Total Valuation
Zymeworks has a market cap or net worth of $984.26 million. The enterprise value is $629.67 million.
Important Dates
The next estimated earnings date is Wednesday, March 5, 2025, after market close.
| Earnings Date | Mar 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Zymeworks has 68.88 million shares outstanding. The number of shares has increased by 10.38% in one year.
| Current Share Class | 68.88M |
| Shares Outstanding | 68.88M |
| Shares Change (YoY) | +10.38% |
| Shares Change (QoQ) | -0.31% |
| Owned by Insiders (%) | 0.20% |
| Owned by Institutions (%) | 60.83% |
| Float | 39.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.21 |
| Forward PS | 9.94 |
| PB Ratio | 2.71 |
| P/TBV Ratio | 2.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 10.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.10, with a Debt / Equity ratio of 0.06.
| Current Ratio | 4.10 |
| Quick Ratio | 3.82 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -28.73% and return on invested capital (ROIC) is -18.29%.
| Return on Equity (ROE) | -28.73% |
| Return on Assets (ROA) | -14.69% |
| Return on Capital (ROIC) | -18.29% |
| Revenue Per Employee | $223,737 |
| Profits Per Employee | -$408,888 |
| Employee Count | 278 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4.35M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +44.64% in the last 52 weeks. The beta is 1.10, so Zymeworks's price volatility has been similar to the market average.
| Beta (5Y) | 1.10 |
| 52-Week Price Change | +44.64% |
| 50-Day Moving Average | 14.42 |
| 200-Day Moving Average | 11.47 |
| Relative Strength Index (RSI) | 52.48 |
| Average Volume (20 Days) | 552,793 |
Short Selling Information
The latest short interest is 4.15 million, so 6.02% of the outstanding shares have been sold short.
| Short Interest | 4.15M |
| Short Previous Month | 4.34M |
| Short % of Shares Out | 6.02% |
| Short % of Float | 10.49% |
| Short Ratio (days to cover) | 8.11 |
Income Statement
In the last 12 months, Zymeworks had revenue of $62.20 million and -$113.67 million in losses. Loss per share was -$1.52.
| Revenue | 62.20M |
| Gross Profit | -62.46M |
| Operating Income | -122.60M |
| Pretax Income | -115.98M |
| Net Income | -113.67M |
| EBITDA | -114.71M |
| EBIT | -122.60M |
| Loss Per Share | -$1.52 |
Full Income StatementBalance Sheet
The company has $297.20 million in cash and $20.28 million in debt, giving a net cash position of $354.59 million or $5.15 per share.
| Cash & Cash Equivalents | 297.20M |
| Total Debt | 20.28M |
| Net Cash | 354.59M |
| Net Cash Per Share | $5.15 |
| Equity (Book Value) | 366.98M |
| Book Value Per Share | 5.27 |
| Working Capital | 259.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$54.58 million and capital expenditures -$2.03 million, giving a free cash flow of -$56.62 million.
| Operating Cash Flow | -54.58M |
| Capital Expenditures | -2.03M |
| Free Cash Flow | -56.62M |
| FCF Per Share | -$0.82 |
Full Cash Flow StatementMargins
Gross margin is -100.42%, with operating and profit margins of -197.11% and -182.75%.
| Gross Margin | -100.42% |
| Operating Margin | -197.11% |
| Pretax Margin | -189.75% |
| Profit Margin | -182.75% |
| EBITDA Margin | -184.42% |
| EBIT Margin | -197.11% |
| FCF Margin | n/a |
Dividends & Yields
Zymeworks does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.38% |
| Shareholder Yield | -10.38% |
| Earnings Yield | -11.55% |
| FCF Yield | -5.75% |
Analyst Forecast
The average price target for Zymeworks is $19.17, which is 34.15% higher than the current price. The consensus rating is "Buy".
| Price Target | $19.17 |
| Price Target Difference | 34.15% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 13.98% |
| EPS Growth Forecast (5Y) | -9.92% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zymeworks has an Altman Z-Score of 1.06 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.06 |
| Piotroski F-Score | 1 |